


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
APPLICATION FOR CLINICAL TRIAL OF TQB3142 “Bcl-xL PROTAC”
ACCEPTED BY NMPA

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the Investigational New Drug (IND) application for TQB3142 “Bcl-xL PROTAC (proteolysis targeting chimera)”, an innovative drug intended for the treatment of malignant tumors independently developed by the Group has been accepted by the National Medical Products Administration of China (NMPA).

TQB3142 is a PROTAC molecule that specifically degrades the Bcl-xL protein by targeting it through the ubiquitin-proteasome system, in order to curtail Bcl-xL protein’s inhibition of tumour apoptosis, thereby activating the Caspase cascade response and inducing apoptosis in tumour cells. Studies have shown that TQB3142 exhibits significant antitumor activity in multiple transplanted tumour models, with lower platelet toxicity risk than comparable drug candidates, thus allowing a more favourable therapeutic window and controllable metabolic risks.

Currently, there are no Bcl-xL inhibitors approved for marketing worldwide. TQB3142 is an anti-tumor drug with a novel mechanism of action. Through its optimised molecular design, TQB3142 maintains its degradation activity while reducing the risk of haematological toxicity, and is expected to be a new treatment option for patients suffering malignant tumors.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 12 August 2025

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.